Adding Imaavy (nipocalimab-aahu) to standard treatment reduces hospital days by as much as 68% and lowers estimated annual hospital costs by $11,000 to $13,000 per patient for adults with generalized myasthenia gravis (gMG). That’s according to a post hoc analysis of data from the global Phase 3…
News
Argenx is advancing a clinical trial evaluating whether adding the experimental therapy empasiprubart to Vyvgart (efgartigimod alfa-fcab) can improve disease control in people with generalized myasthenia gravis (gMG) whose symptoms are only partly controlled with Vyvgart alone. The Phase 2a clinical trial, called ADAPT-Forward 1 (NCT07284420), is…
Kyverna Therapeutics and ElevateBio have signed a manufacturing and supply agreement for mivocabtagene autoleucel (miv-cel), Kyverna’s experimental CAR T-cell therapy for people with generalized myasthenia gravis (gMG). The new agreement covers both U.S. commercial and global clinical supply of miv-cel, formerly known as KYV-101, which is currently…
The Muscular Dystrophy Association (MDA) brought its Engage Community Seminar to Hershey, Pennsylvania, on July 18, uniting individuals with neuromuscular diseases, caregivers, and medical experts for a day of education and connection. Hosted in collaboration with the Penn State Health Milton S. Hershey Medical Center, the one-day event featured a…
Early treatment with a single low dose of rituximab rapidly eases symptoms and reduces use of corticosteroids in people with generalized myasthenia gravis (gMG) and antibodies against the acetylcholine receptor (AChR) protein, a small real-world study shows. Most of the 17 patients in the study improved within three months…
Among people with generalized myasthenia gravis (gMG) who undergo surgical removal of a thymus gland tumor, use of the approved infusion therapy Vyvgart (efgartigimod) — both before and after surgery — may help stabilize disease activity and reduce the risk of the condition worsening. That’s according to data…
Living with generalized myasthenia gravis (gMG) can make day-to-day life feel uncertain. Plans are dictated by energy levels, muscle strength, how it feels to breathe or swallow, vision problems, and how those symptoms change over the course of a day.1,2 A task that feels manageable in the morning might feel…
TPST-4003, Tempest Therapeutics’ next-generation CAR T-cell therapy for autoimmune diseases such as myasthenia gravis (MG), will soon be tested in people for the first time, the developer announced. The upcoming investigator-initiated clinical trial, to be conducted in China by Senlang Biotechnology, will assess the effects of this new…
Repeated cycles of Rystiggo (rozanolixizumab-noli) were generally well tolerated and consistently eased symptoms over a median study duration of about two years among people with generalized myasthenia gravis (gMG). That’s according to a final analysis of pooled data from the global Phase 3 MycarinG clinical trial (NCT03971422) and…
Thymectomy, or the surgical removal of the thymus gland, may help people with myasthenia gravis (MG) achieve and maintain disease remission without the need for other treatments, according to a study in China. Thymectomy was significantly associated with a threefold higher chance of achieving that outcome, called maintained…
Recent Posts
- Thymus changes may play larger role in late-onset myasthenia gravis
- 3 symptoms of myasthenia gravis that are often misunderstood
- Myasthenia gravis tied to substantial employment losses in Spain
- After a long hike, I want to keep discovering what my body can do
- From the Dealership to Diagnosis: One Man’s Journey with gMG